SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 16th, 2017 • Rosetta Genomics Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 3, 2017, between Rosetta Genomics Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
WARRANT TO PURCHASE ORDINARY SHARES ROSETTA GENOMICS LTD.Warrant Agreement • August 16th, 2017 • Rosetta Genomics Ltd. • Pharmaceutical preparations • New York
THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Authorized Shares Increase Date (the “Initial Exercise Date”) and on or prior to 5:00 PM New York City time on the fifth anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Rosetta Genomics Ltd., an Israeli company (the “Company”), up to 649,635 Ordinary Shares, NIS 7.2 par value (the “Ordinary Share(s)”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
